Weekly Digest's Investor Essentials Special Report Identifies Unique Investing Opportunities in the H1N1 'Swine Flu' Outbreak
October 14 2009 - 11:06AM
PR Newswire (US)
PRINCETON, N.J., Oct. 14 /PRNewswire/ -- Weekly Digest
(http://www.bullmarket.com/digest), a free investment research
publication, announced the publication of a special report on
investment opportunities in the connection with the H1N1 "Swine
Flu" Outbreak, including updated outlooks for Gilead Sciences
(NASDAQ:GILD), Sinovac Biotech (AMEX:SVA), Dynavax Technologies
(NASDAQ:DVAX), Hemispherx BioPharma (AMEX:HEB), BioCryst
Pharmaceuticals (NASDAQ:BCRX) and several others. After posting
large gains throughout 2009, swine flu stocks are seeing their
largest pullback yet. For investors looking to position their
portfolios for flu season, there are more ways to trade the flu
than ever. Investors have large-cap pharmaceutical plays to choose
from, and some of the more volatile, small-cap names have proven
the efficacy of their drugs, while others are too far behind in
their clinical trials to capitalize on the current pandemic. To
receive a free, 23-page report offering in depth analysis of the
various participants in the vaccine and antiviral market, as well
as some peripheral plays focusing directly on the impact of the
current H1N1 swine flu pandemic, please visit the following link:
http://www.bullmarket.com/digest/signup.php?refer=pr1_swineflu The
report covers these topics and more recent reports: -- Which
small-cap swine flu plays have a real chance of benefiting in the
event of a serious H1N1 outbreak and which are riding on the hype?
-- What sets Sinovac apart from other small caps pursuing vaccines
and treatments to fight swine flu? How robust is Sinovac's array of
products? -- Is BioCryst likely to see revenue from its flu
treatment during this flu season? How does BioCryst's peramivir
fare against established drugs Tamiflu and Relenza? What are the
downside risks facing BioCryst after its strong run higher? -- Is
Dynavax a real swine flu play? What do Dynavax investors need to
know about the company's swine flu efforts? -- How important is
Tamiflu to Gilead's business? What are the mechanics of Gilead's
Tamiflu royalty arrangement with Roche? What are the threats to
Tamiflu's dominance in the antiviral market? About Weekly Digest:
Weekly Digest is a free publication offering first-rate stock
research, analysis, and commentary that is independently published
by leading investment services. Subscribers receive a weekly
newsletter as well as regular Special Reports, such as the new
report Investor Essentials: Picking Winners for Pandemic Profits.
NOTE: This release was published by Indie Research Advisors, LLC, a
registered investment advisor with CRD #131926. Interested parties
may visit adviserinfo.sec.gov for additional information. Past
performance does not guarantee future results. Investors should
always research companies and securities before making any
investments. Nothing herein should be construed as an offer or
solicitation to buy or sell any security. CONTACT: Marcia Martin,
+1-888-278-5515 DATASOURCE: Indie Research Advisors, LLC CONTACT:
Marcia Martin, +1-888-278-5515 Web Site:
http://www.bullmarket.com/digest
Copyright